Certified according to
DIN EN ISO 13485:2016
RBC-FluoGene® Q
RBC-FluoGene® Q
The flexible blood group diagnostics for every Real-time cycler
The new FluoGene® Q series consists of liQuid mixes and is detached from the inno-train instruments and the FluoGene® software. The qPCR kits consist of a few, usually 1-2, primer-probe mixes, the FluoMix, and one positive and one negative control DNA. The reagents can be used on any Real-time instrument in both 96 and 384 blocks.
Advantages of the RBC-FluoGene® Q
qPCR in liquid format for flexible screening.
Control DNA included in the kit.
Only one pipetting step.
Less than 5 minutes hands-on time.
80 minutes from DNA to result.
Suitable for any Real-time PCR instrument.
25 years of experience in RBC genotyping.
RBC-FluoGene® fetal RHD Q
Fetal RHD genotyping from maternal plasma is a groundbreaking technique in prenatal diagnostics. This non-invasive method offers crucial insights into the RhD blood type status of the fetus, thereby aiding in the management of RhD alloimmunization potentially leading to hemolytic disease of the newborn (HDN). The clinical implications of fetal RHD genotyping are significant. For RhD-negative mothers carrying RhD-positive fetuses, knowledge of the fetal RhD status allows for timely interventions to prevent RhD alloimmunization.
These interventions may include administration of Rh immunoglobulin (RhIg) to suppress the maternal immune response, thus reducing the risk of HDN in subsequent pregnancies. Conversely, RhD-negative fetuses can be identified early, sparing unnecessary RhIg administration and associated costs.
Downloads
Flyer RBC-FluoGene® fetal RHD Q
Products:
RBC-FluoGene Q
| Item number | Name |
|---|---|
| 001 096 030Q | RBC-FluoGene fetal RHD Q |
